Lakewood-based KRTL Holding Group Inc. (OTC: KRTL) subsidiary KRTL Biotech Inc. has completed the registration process with the U.S. Food and Drug Administration (FDA). This achievement is a key part of KRTL’s goal to strengthen the U.S. pharmaceutical supply chain by integrating international manufacturers and improving health care access both nationally and globally.
By meeting FDA standards, KRTL Biotech is prepared to assist international pharmaceutical manufacturers in supplying high-quality active pharmaceutical ingredients (APIs), novel compounds and finished products to the U.S. market following the establishment of dedicated manufacturing facilities.
This milestone positions KRTL Biotech for corporate growth. Shareholders of KRTL Holding Group are expected to see advantages from the FDA registration through increased partnership opportunities and market presence within the pharmaceutical sector.
KRTL plans to further its influence by launching a state-of-the-art manufacturing and distribution facility in 2025. This facility will help boost production capacity, improve distribution logistics and support both domestic and international partners.
“Securing FDA registration represents a pivotal moment for KRTL Biotech, one that enables us to make a substantial contribution to the global pharmaceutical ecosystem,” said Cesar Herrera, CEO of KRTL Holding Group Inc.
KRTL Holding Group Inc. specializes in mergers, acquisitions and strategic partnerships, operating through subsidiaries KRTL Biotech Inc. and KRTL International Corp.
